Brokerages Set Arrowhead Pharmaceuticals, Inc. (ARWR) PT at $2.00

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $2.00.

ARWR has been the topic of a number of recent research reports. Jefferies Group LLC reissued a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. Piper Jaffray Companies reissued a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 target price (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. Finally, William Blair raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th.

COPYRIGHT VIOLATION WARNING: “Brokerages Set Arrowhead Pharmaceuticals, Inc. (ARWR) PT at $2.00” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://sportsperspectives.com/2017/10/11/brokerages-set-arrowhead-pharmaceuticals-inc-arwr-pt-at-2-00.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in Arrowhead Pharmaceuticals by 3.7% during the first quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock worth $581,000 after purchasing an additional 11,099 shares during the period. Teachers Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 18.0% during the fourth quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 17,201 shares during the period. Geode Capital Management LLC lifted its stake in Arrowhead Pharmaceuticals by 3.4% during the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 21,654 shares during the period. Virtu KCG Holdings LLC lifted its stake in Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 53,215 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its stake in Arrowhead Pharmaceuticals by 414.7% during the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 53,500 shares during the period. Hedge funds and other institutional investors own 20.61% of the company’s stock.

Shares of Arrowhead Pharmaceuticals (ARWR) traded up 2.76% during midday trading on Friday, hitting $4.10. The stock had a trading volume of 1,037,230 shares. The firm’s market cap is $306.57 million. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $7.09. The firm has a 50-day moving average price of $3.48 and a 200-day moving average price of $2.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The business had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. On average, equities analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply